The delivery of NAD+ precursors, such as nicotinic acid, to AML cells by bone marrow stromal cells through gap junctions reduces the effectiveness of NAMPT inhibitors, indicating the necessity of investigating combination treatment regimens using NAPRT inhibitors, such as 2-hydroxynicotinic acid. The gene discussed is NAMPT; the disease is acute myeloid leukemia.